Top sales executive deepens expertise in bringing genetic testing to personalized medicine
August 18, 2011 – Chalfont, Pennsylvania – Genomind, LLC, a company focused on neuropsychiatric personalized medicine, announced the addition of Thomas D. Bartel as Chief Sales Officer, to further expand adoption of the Genecept Assay, a biomarker test designed to help inform treatment options for patients with mood disorders. Mr. Bartel has an impressive track record of consistently increasing revenue and profit growth at new and established healthcare companies alike, including Quest Diagnostics, Ipsogen, and American Clinical Services.
“Tom Bartel has generated exceptional sales results for more than 20 years,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind. “He joins an executive team that is excited to be leading efforts aimed at increasing adoption of the Genecept Assay by psychiatrists, nurse practitioners, primary care physicians, and other clinicians seeking to use neurotransmitter-based data to transform their ability to help their patients.”
Mr. Bartel is Chief Sales Officer, responsible for leading all sales and commercialization efforts for Genomind. Mr. Bartel has a strong track record of building successful sales teams and consistently exceeding revenue targets and profitability goals for more than two decades. He was most recently Vice President of Sales for Ipsogen, a worldwide molecular diagnostics company. He previously directed the overall national sales strategy and $500 million growth of genomic and esoteric testing at Quest Diagnostics and drove revenue growth at American Clinical Services before the company was purchased by Sonic Healthcare Group. Mr. Bartel has a Bachelor of Science in Industrial Engineering from Rutgers University.
About Genomind, LLC: Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Lombard, a neurologist, is co-founder of Genomind and is a nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind